Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Clinical Research and Equipment Industry Analysis
UpdatedJun 17, 2026
DataAggregated Company Financials
Companies11
- 7D-5.4%
- 3M-5.1%
- 1Y-6.6%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 2.2%, driven by a pullback from Locus Cell of 14%. Meanwhile, DuoGenic StemCells actually outperformed within the industry, gaining 8.7% in the last week. The industry has fallen 5.2% in the last year.
Industry Valuation and Performance
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 17 Jun 2026 | NT$30.8b | NT$2.7b | -NT$747,832,000.00 | 21.3x | -41.2x | 11.6x |
| Fri, 15 May 2026 | NT$32.4b | NT$2.5b | -NT$764,028,000.00 | 21.7x | -42.4x | 12.9x |
| Sun, 12 Apr 2026 | NT$31.1b | NT$2.5b | -NT$767,980,000.00 | 21.8x | -40.5x | 12.4x |
| Tue, 10 Mar 2026 | NT$31.2b | NT$2.4b | -NT$692,870,000.00 | 19.1x | -45x | 12.9x |
| Thu, 05 Feb 2026 | NT$33.7b | NT$2.4b | -NT$689,929,000.00 | 24.2x | -48.9x | 13.9x |
| Sat, 03 Jan 2026 | NT$34.0b | NT$2.4b | -NT$689,929,000.00 | 25.8x | -49.3x | 14x |
| Mon, 01 Dec 2025 | NT$37.9b | NT$2.4b | -NT$670,921,000.00 | 19.9x | -56.5x | 15.5x |
| Wed, 29 Oct 2025 | NT$36.0b | NT$2.5b | -NT$870,437,000.00 | 18.6x | -41.3x | 14.6x |
| Fri, 26 Sep 2025 | NT$35.7b | NT$2.5b | -NT$870,437,000.00 | 19.8x | -41x | 14.5x |
| Sun, 24 Aug 2025 | NT$35.6b | NT$2.5b | -NT$819,216,000.00 | 20.6x | -43.5x | 14.5x |
| Tue, 22 Jul 2025 | NT$34.3b | NT$2.5b | -NT$600,003,000.00 | 21.9x | -57.2x | 13.9x |
| Thu, 19 Jun 2025 | NT$32.7b | NT$2.5b | -NT$600,003,000.00 | 23.3x | -54.6x | 13.3x |
| Sat, 17 May 2025 | NT$32.0b | NT$2.5b | -NT$604,301,000.00 | 23.4x | -52.9x | 13x |
| Mon, 14 Apr 2025 | NT$30.7b | NT$2.5b | -NT$540,128,000.00 | 23.4x | -56.9x | 12.5x |
| Wed, 12 Mar 2025 | NT$35.9b | NT$2.6b | -NT$851,729,000.00 | 24.6x | -42.1x | 14x |
| Fri, 07 Feb 2025 | NT$37.4b | NT$2.6b | -NT$854,432,000.00 | 24.1x | -43.8x | 14.6x |
| Sun, 05 Jan 2025 | NT$34.5b | NT$2.6b | -NT$854,432,000.00 | 22.8x | -40.4x | 13.5x |
| Tue, 03 Dec 2024 | NT$41.9b | NT$2.6b | -NT$854,432,000.00 | 23.7x | -49x | 16.3x |
| Thu, 31 Oct 2024 | NT$42.3b | NT$2.5b | -NT$712,402,000.00 | 24.2x | -59.3x | 16.8x |
| Sat, 28 Sep 2024 | NT$41.7b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -49.8x | 18.3x |
| Mon, 26 Aug 2024 | NT$40.9b | NT$2.3b | -NT$836,610,000.00 | 22.3x | -48.9x | 18x |
| Wed, 24 Jul 2024 | NT$43.1b | NT$2.1b | -NT$797,765,000.00 | 33.3x | -54x | 20.2x |
| Fri, 21 Jun 2024 | NT$42.3b | NT$2.1b | -NT$797,765,000.00 | 34.3x | -53.1x | 19.8x |
| Sun, 19 May 2024 | NT$40.7b | NT$2.1b | -NT$794,421,000.00 | 32.1x | -51.3x | 19.1x |
| Tue, 16 Apr 2024 | NT$40.1b | NT$2.1b | -NT$903,875,000.00 | 30.5x | -44.4x | 19x |
| Thu, 14 Mar 2024 | NT$40.5b | NT$2.1b | -NT$611,249,000.00 | 32.1x | -66.2x | 19.6x |
| Sat, 10 Feb 2024 | NT$43.0b | NT$2.1b | -NT$610,218,000.00 | 32.4x | -70.4x | 20.7x |
| Mon, 08 Jan 2024 | NT$46.5b | NT$2.1b | -NT$610,218,000.00 | 34.4x | -76.3x | 22.4x |
| Wed, 06 Dec 2023 | NT$48.6b | NT$2.1b | -NT$610,218,000.00 | 34.1x | -79.6x | 23.4x |
| Fri, 03 Nov 2023 | NT$48.8b | NT$2.2b | -NT$497,769,000.00 | 31.8x | -98.1x | 21.9x |
| Sun, 01 Oct 2023 | NT$48.0b | NT$2.2b | -NT$497,769,000.00 | 31.3x | -96.4x | 21.6x |
| Tue, 29 Aug 2023 | NT$43.3b | NT$2.2b | -NT$497,769,000.00 | 31.1x | -87x | 19.5x |
| Thu, 27 Jul 2023 | NT$47.8b | NT$2.5b | -NT$274,767,000.00 | 42.4x | -174.1x | 19.5x |
| Sat, 24 Jun 2023 | NT$48.4b | NT$2.5b | -NT$274,767,000.00 | 43.2x | -176.1x | 19.7x |
Price to Earnings Ratio
-176.1x
Current Industry PE
- Investors are pessimistic on the Taiwanese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 16.8x is higher than the industry's current PS ratio of 11.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 2.6% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 2.34% | |
| Healthcare | -0.066% | |
| Life Sciences | -5.43% | |
| Clinical Research and Equipment | -5.43% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 7607 DuoGenic StemCells | NT$14.40 | 8.7% +NT$35.1m | 41.2% | n/a | |
| 6939 TFBS Bioscience | NT$20.10 | 1.0% +NT$7.0m | -16.9% | n/a | |
| 6848 RBC Bioscience | NT$19.90 | 2.1% +NT$5.7m | 20.9% | PE12.1x | |
| 6662 BioLASCO Taiwan | NT$29.90 | 0.7% +NT$5.1m | -11.4% | PE18x |